Kura CEO Troy Wilson, Ph.D., J.D. will participate in a fireside chat at the Stifel Targeted Oncology Forum on April 8, discussing the progress across our pipeline of precision medicines. Learn more and access the webcast: https://lnkd.in/gBfxPTeP
Kura CEO Troy Wilson, Ph.D., J.D. will participate in a fireside chat at the Stifel Targeted Oncology Forum on April 8, discussing the progress across our pipeline of precision medicines. Learn more and access the webcast: https://lnkd.in/gBfxPTeP
Troy Wilson Costello syndrome is caused by mutations in HRAS. Tipifarnib or your next gen FTI might help individuals with CS where there is great unmet need. Would Kura Oncology, Inc. consider working with RASopathies Network to advance research in this area?